<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Molecular pathogenesis of congenital erythrocytoses and polycythemia vera
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Molecular pathogenesis of congenital erythrocytoses and polycythemia vera
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Molecular pathogenesis of congenital erythrocytoses and polycythemia vera
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Josef T Prchal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 23, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythrocytosis and polycythemia are interchangeable terms for an elevated level of hemoglobin (Hb) or hematocrit (Hct). No clear consensus for either term has been achieved, but in this topic we use the term polycythemia only with reference to polycythemia vera (PV), while we use erythrocytosis to describe various polyclonal disorders that cause elevated Hb/Hct.
        </p>
        <p>
         Erythrocytosis can result from increased red blood cell (RBC) mass (absolute erythrocytosis) and/or decreased intravascular volume (relative erythrocytosis). Absolute erythrocytosis can be caused by an erythroid progenitor-intrinsic disorder (primary erythrocytosis) or in response to elevated levels of the key regulatory hormone, erythropoietin (EPO), and other causes (secondary erythrocytosis)  (
         <a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Most cases of primary erythrocytosis are due to PV, a myeloproliferative neoplasm caused by an acquired (ie, not inherited) somatic mutation of
         <em>
          JAK2
         </em>
         in bone marrow stem cells. Rare inherited (germline) conditions can cause erythrocytosis due to inherited gene variants that cause augmented hypoxia sensing, increased affinity of Hb for oxygen (O
         <sub>
          2
         </sub>
         ), and other causes.
        </p>
        <p>
         This topic discusses molecular mechanisms associated with inherited (congenital) erythrocytoses and PV.
        </p>
        <p>
         The clinical approach to a patient with erythrocytosis or suspected PV is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">
          "Clinical manifestations and diagnosis of polycythemia vera"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H304980452">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythrocytosis
         </strong>
         – Erythrocytosis, also called polycythemia, describes an elevated hemoglobin (Hb) or hematocrit (Hct).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adults
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Increased Hb
         </strong>
         – &gt;17.5 g/dL in adult males or &gt;15.3 g/dL in non-pregnant females [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Increased Hct
         </strong>
         – &gt;50 percent in males or &gt;45 percent in females
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children
         </strong>
         – For children, normal values for red blood cell (RBC) parameters vary with age  (
         <a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to age and sex  (
         <a class="graphic graphic_table graphicRef127504" href="/z/d/graphic/127504.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">
          table 2
         </a>
         ), altitude of residence is an independent variable for defining erythrocytosis. Adjustments for a given population, sex, age, and the altitude of residence have been published [
         <a href="#rid2">
          2
         </a>
         ]. Even moderate altitude should be considered when interpreting erythrocytosis, as normal values for Hb/Hct are significantly higher in Denver or Salt Lake City compared with New York or Los Angeles [
         <a href="#rid3">
          3
         </a>
         ]. Analysis of 71,798 Swiss males aged 18 to 22 years showed significant Hb differences with the altitude of residence between 200 and 2000 meters [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Absolute versus relative
         </strong>
         <strong>
          erythrocytosis
         </strong>
         – Erythrocytosis can be caused by increased RBC mass (absolute erythrocytosis) or by volume contraction, without an increase in RBC mass (relative erythrocytosis). Numerous conditions can cause erythrocytosis  (
         <a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evaluation of the cause of erythrocytosis/polycythemia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary erythrocytosis
         </strong>
         – RBC-intrinsic erythrocytosis caused by an acquired (ie, not inherited) mutation in hematopoietic cells or by an inherited (ie, germline) gene variant that renders proliferation of erythroid progenitors independent of or hypersensitive to serum levels of erythropoietin (EPO).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Secondary erythrocytosis
         </strong>
         – Erythrocytosis caused by excessive EPO or other non-RBC-intrinsic conditions. This can be an appropriate physiologic response (eg, increased EPO from tissue hypoxia caused by lung disease, high carboxy-hemoglobin in cigarette smokers, methemoglobinemia, or inheritance of high oxygen affinity Hbs) or an inappropriate (ie, not physiologic) response, such as an EPO-secreting tumor or "blood doping."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed
         </strong>
         <strong>
          (ie, primary and secondary) disorders
         </strong>
         – Some disorders share features of both primary and secondary erythrocytosis (eg, Chuvash erythrocytosis).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          REGULATION OF ERYTHROPOIESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythropoiesis is the process of production and renewal of the red blood cell (RBC) mass. A brief review of basic aspects of erythropoiesis is presented below to allow for a better understanding of the potential mechanisms by which erythrocytosis can occur. A more detailed discussion of the regulation of erythropoiesis is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">
          "Regulation of erythropoiesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Erythropoietin (EPO)
         </span>
         <span class="headingEndMark">
          —
         </span>
         EPO is the principal hormone that regulates erythropoiesis in adults. EPO is primarily produced by cells in the kidney, while a small amount is produced in the liver. EPO is required at various stages of erythroid maturation [
         <a href="#rid5">
          5
         </a>
         ]. In adult erythropoiesis, EPO is most important for terminal maturation of erythroid cells, acting especially at the level of the early and late committed erythroid progenitor cells  (
         <a class="graphic graphic_figure graphicRef70092" href="/z/d/graphic/70092.html" rel="external">
          figure 1
         </a>
         ). By contrast, pluripotent hematopoietic stem cells (HSCs) and early progenitor cells require stem cell factor, thrombopoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF), and/or interleukin (IL)-3 for growth, in addition to EPO.
        </p>
        <p class="headingAnchor" id="H3263173289">
         <span class="h2">
          Erythropoietin receptor (EPO-R)
         </span>
         <span class="headingEndMark">
          —
         </span>
         EPO effects are mediated by EPO-R, an EPO-specific receptor that is expressed as a cell surface homodimer on erythroid progenitor cells [
         <a href="#rid6">
          6
         </a>
         ]. The interaction of EPO with EPO-R leads to conformational changes of the EPO-R homodimer and activation of intracellular signals:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stimulation of proliferation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction of erythroid-specific protein expression and their activation, and also cellular differentiation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibition of apoptosis
        </p>
        <p>
        </p>
        <p>
         The cytoplasmic portion of the EPO-R, distal to the transmembrane domain, is a positive regulatory domain that interacts with Janus 2 tyrosine kinase (JAK2) [
         <a href="#rid7">
          7
         </a>
         ]. Soon after interacting with EPO-R, JAK2 phosphorylates itself and the STAT5 transcription factor, which initiates a cascade of erythroid-specific signaling and inhibition of apoptosis [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The C-terminal cytoplasmic domain of EPO-R functions as a negative regulatory domain [
         <a href="#rid7">
          7
         </a>
         ]. Hematopoietic cell phosphatase (HCP; also called SH protein tyrosine phosphatases [SHP-1, SH-PTP1]) interacts with this portion of EPO-R and downregulates signal transduction [
         <a href="#rid9">
          9
         </a>
         ]. Mutants lacking this portion of EPO-R are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2 and increased erythroid progenitor proliferation [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Gain-of-function mutations of
         <em>
          EPOR
         </em>
         have been found in patients with primary familial and congenital erythrocytosis/polycythemia, as described below. (See
         <a class="local">
          'Primary familial and congenital erythrocytosis/polycythemia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Oxygen sensor
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major stimulus for EPO production is decreased oxygen (O
         <sub>
          2
         </sub>
         ) delivery caused by anemia (reduced RBC mass) or decreased O
         <sub>
          2
         </sub>
         saturation of hemoglobin (hypoxemia) [
         <a href="#rid10">
          10-13
         </a>
         ]. Factors that regulate
         <em>
          EPO
         </em>
         transcription are referred to as a cellular oxygen sensor  (
         <a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. This process is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">
          "Regulation of erythropoiesis", section on 'Hypoxia-inducible factor and the response to hypoxia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxia inducible factors (HIFs)
         </strong>
         – Hypoxic stimulation of the O
         <sub>
          2
         </sub>
         sensor signaling pathway increases production of HIF-1 and HIF-2; HIF-2 is the principal regulator of
         <em>
          EPO
         </em>
         gene transcription [
         <a href="#rid15">
          15
         </a>
         ]. Protein levels of HIF-1 and HIF-2 alpha subunits are stabilized by hypoxia, while they decay rapidly in normoxia [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HIF-1 and HIF-2 are essential for life; they play important roles in cellular adaptation to hypoxia by controlling transcription of
         <em>
          EPO
         </em>
         and other genes required for erythropoiesis. HIFs regulate levels of vascular endothelial growth factor (VEGF) and its receptor, energy metabolism (eg, the glucose transporter and glycolytic enzymes), iron metabolism (ie, hepcidin and transferrin receptor), and cellular development. HIFs also play a major role in cancer and facilitate energy metabolism of cancer cells (ie, the Warburg effect) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Control of HIF protein levels
         </strong>
         – HIF alpha subunit isoforms (HIF-1 alpha, HIF-2 alpha, HIF-3 alpha) are rapidly destroyed in the presence of O
         <sub>
          2
         </sub>
         by a mechanism that involves prolyl hydroxylation by the iron-dependent enzyme, PHD2 (encoded by
         <em>
          EGLN
         </em>
         ). Prolyl hydroxylated HIF alpha subunits bind to the VHL tumor suppressor protein, which leads to ubiquitylation and rapid proteasomal degradation of HIF alpha by an E3 ligase complex.
        </p>
        <p>
        </p>
        <p>
         Mutations of genes involved in the oxygen sensor pathway  (
         <a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">
          figure 2
         </a>
         ) have been associated with various congenital erythrocytoses. (See
         <a class="local">
          'EGLN1 mutations'
         </a>
         below and
         <a class="local">
          'EPAS1 mutations'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other regulators of erythropoiesis
         </strong>
         – Insulin-like growth factor-I (IGF-I) and angiotensin II contribute to erythropoiesis, but they have not been shown to cause congenital erythrocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IGF-I
         </strong>
         – IGF-I has EPO-like activity that targets circulating early erythroid progenitors [
         <a href="#rid18">
          18,19
         </a>
         ]. IGF-I may play a role in patients with end-stage kidney disease and with post-renal transplant erythrocytosis. (See
         <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">
          "Kidney transplantation in adults: Posttransplant erythrocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Angiotensin II
         </strong>
         – Inhibitors of angiotensin converting enzyme (ACE), such as
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         or
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         , lower hematocrit in patients with post-transplant erythrocytosis and may act through JAK2. Post-transplant erythrocytosis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">
          "Kidney transplantation in adults: Posttransplant erythrocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          The iron regulatory protein (IRP-1)
         </strong>
         – Hypoxic regulation of iron availability and erythropoiesis are closely related. Iron deficiency inhibits PHD2 and augments levels of HIFs, while it has an opposite effect on erythropoiesis (ie, it represses HIF-2 alpha by the direct interaction of iron and HIF-2 alpha). The iron regulatory protein (IRP-1) binds to the iron-responsive element in the untranslated region of 5' HIF-2 alpha and represses its translation. Northern European families have been described with pathologic variants of
         <em>
          IRP1
         </em>
         in association with erythrocytosis, and deletion of Irp1 in mice caused erythrocytosis [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1610467985">
         <span class="h1">
          CONGENITAL ERYTHROCYTOSES
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Augmented hypoxia-sensing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypoxia-sensing is central to the regulation of erythrocytosis and other physiologic functions [
         <a href="#rid12">
          12,21
         </a>
         ]. Mutations of genes in hypoxia-sensing pathways were identified because of their association with erythrocytosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           VHL
          </em>
         </strong>
         – Chuvash erythrocytosis and other
         <em>
          VHL
         </em>
         gene mutations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           EGLN1
          </em>
         </strong>
         – Loss-of-function mutations of
         <em>
          EGLN1
         </em>
         (encoding proline hydroxylase 2 [PHD2])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           EPAS1
          </em>
         </strong>
         – Gain-of-function mutations of
         <em>
          EPAS1
         </em>
         (encoding hypoxia inducible factor [HIF]-2 alpha)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           IRP1 –
          </em>
         </strong>
         Loss-of-function mutations of iron regulatory protein (IRP-1)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Chuvash erythrocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         This entity, also called Chuvash polycythemia, is a rare congenital polycythemia caused by a mutation of the von Hippel-Lindau gene (
         <em>
          VHL
         </em>
         ). This condition has features of both primary and secondary erythrocytosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – Chuvash erythrocytosis is a congenital erythrocytosis associated with thrombotic or hemorrhagic vascular complications and pulmonary hypertension, which is associated with early mortality (eg, &lt;40 years) [
         <a href="#rid22">
          22,23
         </a>
         ]. Levels of serum erythropoietin (EPO) are elevated or inappropriately normal for the level of hematocrit (Hct), while serum hepcidin levels are reduced [
         <a href="#rid22">
          22,24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Phlebotomy is not warranted for Chuvash erythrocytosis. Phlebotomy may increase the rate of thrombotic complications because iron deficiency inhibits PHD2 and augments levels of HIFs, which augment expression of prothrombotic factors [
         <a href="#rid24">
          24,26-28
         </a>
         ]. In one report, the JAK2 inhibitor
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         decreased phlebotomy requirements in patients with Chuvash erythrocytosis [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Chuvash erythrocytosis arises sporadically, but it is endemic in the Chuvash population of the mid-Volga region of European Russia and on the Italian island, Ischia [
         <a href="#rid30">
          30-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Chuvash erythrocytosis is caused by the
         <em>
          VHL
         </em>
         R200W mutation. The role of
         <em>
          VHL
         </em>
         in regulating erythropoiesis is discussed above. (See
         <a class="local">
          'Oxygen sensor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <em>
          VHL
         </em>
         R200W mutation is present in both alleles of affected patients and in one allele of carriers. Most other
         <em>
          VHL
         </em>
         mutations are associated with characteristic VHL-related tumors (eg, pheochromocytoma, renal cell carcinoma, and hemangioblastomas), rather than congenital polycythemia; however, some cases of acquired polycythemia may be related to excessive EPO produced by such tumors [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other homozygous and compound heterozygous germline mutations of
         <em>
          VHL
         </em>
         are associated with erythrocytosis, but not with VHL tumor syndrome, including Croatian erythrocytosis (
         <em>
          VHL
         </em>
         H191D),
         <em>
          VHL
         </em>
         exon 2 mutation (
         <em>
          VHL
         </em>
         P138L), alternative splicing with exon 2 skipping, other compound heterozygous germline mutations (eg,
         <em>
          VHL
         </em>
         T124A and
         <em>
          VHL
         </em>
         L188V), and homozygous c.222C→A, p.V74V) [
         <a href="#rid39">
          39-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          <i>
           EGLN1
          </i>
          mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autosomal dominant erythrocytosis is associated with loss-of-function mutations of
         <em>
          EGLN1
         </em>
         , which encodes PHD2 (prolyl hydroxylase domain protein 2), an enzyme involved in the degradation of HIF alpha under normoxic conditions [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'Oxygen sensor'
         </a>
         above.)
        </p>
        <p>
         A study of 67 patients with spontaneous or familial erythrocytosis identified mutations in the catalytic domain of PHD2 [
         <a href="#rid45">
          45
         </a>
         ]. All gene variants were germline, heterozygous, missense loss-of-function mutations and coded for a predicted full-length mutant PHD2 protein; a non-erythroid phenotype has not been identified with these mutations [
         <a href="#rid12">
          12
         </a>
         ]. Inhibitors of PHD2 may be of clinical interest for therapy of anemia associated with chronic kidney disease. However, compared with EPO, a PHD2 inhibitor was associated with higher rates of thrombosis in a phase 3 trial and it was not approved by the US Food and Drug Administration [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Gain-of-function mutations of
         <em>
          EGLN1
         </em>
         (Asp4Glu; Cys127Ser) may contribute to protection of Tibetans from the development of erythrocytosis at high altitude [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          <i>
           EPAS1
          </i>
          mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autosomal dominant familial erythrocytosis has been associated with a gain-of-function germline mutation in
         <em>
          EPAS1
         </em>
         , which encodes HIF-2 alpha and renders HIF-2 alpha less susceptible to hydroxylation by PHD2 [
         <a href="#rid48">
          48-51
         </a>
         ]. (See
         <a class="local">
          'Oxygen sensor'
         </a>
         above.)
        </p>
        <p>
         Affected individuals usually present with congenital erythrocytosis and elevated or inappropriately normal EPO levels for the given level of Hct. Some patients with congenital erythrocytosis associated with mutations of
         <em>
          EPAS1
         </em>
         develop recurrent pheochromocytomas, paragangliomas, and/or somatostatinomas [
         <a href="#rid52">
          52,53
         </a>
         ]. The tumors are heterozygous for gain-of-function mutations of
         <em>
          EPAS1
         </em>
         , and
         <em>
          EPO
         </em>
         transcripts are present in the tumor. The mutations are in the vicinity of the primary hydroxylation site of the HIF-2 alpha protein, leading to increased HIF-2 alpha activity, prolonged protein half-life, and upregulation of the hypoxia-responsive genes,
         <em>
          EPO
         </em>
         ,
         <em>
          VEGFA
         </em>
         ,
         <em>
          GLUT1
         </em>
         , and
         <em>
          END1
         </em>
         in the tumors [
         <a href="#rid54">
          54,55
         </a>
         ]. The association may result from embryonic mosaicism, because the mutations are generally not found in non-tumor tissues.
        </p>
        <p class="headingAnchor" id="H2160418621">
         <span class="h2">
          Increased oxygen affinity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased affinity of hemoglobin (Hb) for O
         <sub>
          2
         </sub>
         (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ) causes tissue hypoxia and results in congenital erythrocytosis.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Hb mutants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital erythrocytosis due to high O
         <sub>
          2
         </sub>
         affinity Hb mutants is uncommon, but mutations of alpha, beta, and gamma globin genes have been described that lead to autosomal dominant erythrocytosis. (See
         <a class="medical medical_review" href="/z/d/html/7164.html" rel="external">
          "Hemoglobin variants that alter hemoglobin-oxygen affinity"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxygen binding by Hb
         </strong>
         – The Hb tetramer oscillates between the R (relaxed; fully oxygenated hemoglobin) and T (tense; fully deoxygenated hemoglobin) states and requires interactions between globin subunits. The high affinity conformation is due to stabilizing the R state or destabilizing the low affinity T state. Increased O
         <sub>
          2
         </sub>
         affinity has been associated with single point substitutions, double point substitutions, deletions, insertions, reading frame shift mutations, and fusion genes [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alteration in areas of the molecule directly involved in the R→T transition, such as in Hb Chesapeake and Hb Montefiore
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A change of the alpha1:beta1 interface, such as in Hb Crete
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A mutation reducing the affinity of Hb for 2,3-BPG, such as is seen in Hb Rahere and Hb Providence
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elongation of chains by termination codon or frame-shift mutations
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A complete list of high affinity hemoglobins can be found on the Globin Gene Server (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fglobin.bx.psu.edu%2F&amp;token=8H3asYqReYgQFFdRgbitkCSQittb6XZHTeX0Dor5YDL1HrTB4H5KCvI%2F29D45586&amp;TOPIC_ID=7106" target="_blank">
          globin.bx.psu.edu
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Affected individuals are generally asymptomatic, since erythrocytosis compensates to maintain adequate tissue O
         <sub>
          2
         </sub>
         delivery. The age at diagnosis varies with the affected subunit. Germline mutations of alpha globin
         <em>
         </em>
         genes are associated with life-long erythrocytosis, while those of beta globin genes are silent at birth, but erythrocytosis develops after the fetal to adult Hb switch at approximately six months of age. Rare gamma globin mutations are associated with transient neonatal erythrocytosis that disappears by approximately six months of age, when most fetal Hb is replaced by adult Hb.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Among patients with erythrocytosis, a high O
         <sub>
          2
         </sub>
         affinity Hb should be considered in those who have an inappropriately normal or an elevated serum EPO concentration, a normal arterial partial pressure of O
         <sub>
          2
         </sub>
         (pO
         <sub>
          2
         </sub>
         ), and normal O
         <sub>
          2
         </sub>
         saturation, especially in those with autosomal dominant pattern of inheritance; these mutations can also arise de novo
         <em>
         </em>
         in a subject whose parents are not affected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The hemoglobin-O
         <sub>
          2
         </sub>
         dissociation curve is the benchmark for diagnosis of a high O
         <sub>
          2
         </sub>
         affinity Hb  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ). The p50 (ie, 50 percent saturation of Hb) can be estimated from
         <strong>
          venous
         </strong>
         blood by measuring the saturation of Hb, pH, and pO
         <sub>
          2
         </sub>
         . Importantly, an accurate p50 value cannot be "calculated" from the arterial pO2, although this is often attempted erroneously. Although not widely available, the hemox-analyzer apparatus is required when accurate p50 and Hill coefficients are needed [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Note that Hb electrophoresis misses some of these mutants and should
         <strong>
          not
         </strong>
         be the initial screening test. (See
         <a class="medical medical_review" href="/z/d/html/13941.html" rel="external">
          "Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Gel-based electrophoresis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Erythrocytosis is an appropriate physiologic response to a high O
         <sub>
          2
         </sub>
         affinity Hb. Patients with a high affinity Hb should not be phlebotomized, as it further decreases tissue O
         <sub>
          2
         </sub>
         delivery.
        </p>
        <p>
        </p>
        <p>
         Further details of diagnosis and management of patients with high O
         <sub>
          2
         </sub>
         affinity Hb are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7164.html" rel="external">
          "Hemoglobin variants that alter hemoglobin-oxygen affinity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Congenital methemoglobinemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methemoglobin is oxidized Hb that contains iron in the ferric state. Auto-oxidation of Hb to methemoglobin occurs spontaneously at a slow rate in normal individuals, which converts a small percent of available Hb to methemoglobin. This process and its clinical effects are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Formation of methemoglobin
         </strong>
         – During the formation of oxyhemoglobin from deoxyhemoglobin and molecular O
         <sub>
          2
         </sub>
         , one electron is partially transferred from heme iron to the bound oxygen, forming a ferric-superoxide anion complex (Fe3+/O2-) [
         <a href="#rid57">
          57
         </a>
         ]. During deoxygenation, most oxygen leaves as O
         <sub>
          2
         </sub>
         , but a small amount of it leaves as a superoxide (O2-) radical. In the latter circumstance, the partially transferred electron is not returned to the iron moiety, leaving the iron in the ferric state and forming methemoglobin:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         HbFe2+/O2   —&gt;   HbFe3+   +   O2-
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ferric hemes of methemoglobin are unable to bind O
         <sub>
          2
         </sub>
         . In addition, the O
         <sub>
          2
         </sub>
         affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased. As a result, the O
         <sub>
          2
         </sub>
         dissociation curve is "left-shifted"  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ) and O
         <sub>
          2
         </sub>
         delivery to the tissues is impaired; this leads to a compensatory erythrocytosis in some affected individuals [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The only physiologically important pathway for reducing methemoglobin back to Hb is the NADH-dependent reaction catalyzed by cytochrome b5 reductase (b5R; also called methemoglobin reductase).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular basis
         </strong>
         – The major cause of hereditary methemoglobinemia is a deficiency of cytochrome b5 reductase. Less common causes are hemoglobin M disease, in which there is a mutated globin that facilitates the oxidation of iron in the ferric state, and extremely rare cytochrome b5 deficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The laboratory diagnosis of methemoglobinemia is based upon analysis of its absorption spectrum, which has peak absorbance at 631 nm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Most individuals with recessively inherited congenital methemoglobinemia from type I cytochrome b5 reductase (enzyme deficiency restricted to erythrocytes) or dominantly inherited hemoglobin M disease are asymptomatic, although some complain of headache and easy fatigue, despite methemoglobin levels as high as 40 percent of total Hb. The main clinical finding is "cyanosis" or slate-blue color of the skin and mucous membranes, which is due to the different absorbance spectrum of methemoglobin compared with oxyhemoglobin. (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Clinical presentation (congenital)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to methemoglobinemia and cyanosis, patients with the less common type II cytochrome b5 reductase also have a deficiency of enzyme activity in non-erythroid cells, which is associated with severe developmental defects and premature death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          2,3-bisphosphoglycerate deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial deficiency of 2,3-BPG (previously known as 2,3-DPG) is a rare cause of congenital secondary erythrocytosis caused by a deficiency of the red blood cell (RBC) enzyme, bisphosphoglyceromutase (BPGM) [
         <a href="#rid59">
          59-61
         </a>
         ]. The resultant increase in Hb-O
         <sub>
          2
         </sub>
         affinity decreases the amount of O
         <sub>
          2
         </sub>
         released peripherally, leading to compensatory erythrocytosis.
        </p>
        <p>
         Only one family with 2,3-BPG deficiency has been studied comprehensively [
         <a href="#rid59">
          59-61
         </a>
         ]. The proband had undetectable BPGM activity and very low 2,3-BPG levels; his children were not polycythemic, a finding compatible with an autosomal recessive disease. The proband and three sisters had compound heterozygosity for mutations in
         <em>
          BPGM
         </em>
         [
         <a href="#rid61">
          61
         </a>
         ]. However, the children had partially reduced enzyme activity and mildly decreased 2,3-BPG levels. Other heterozygous progeny of this enzyme-deficient patient and heterozygous subjects from unrelated families had moderate erythrocytosis, casting doubt on the autosomal recessive mode of its inheritance [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Finding a decreased p50 is a prerequisite for consideration of 2,3-BPG deficiency as a cause of congenital erythrocytosis  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ). In comparison to the high O
         <sub>
          2
         </sub>
         affinity Hbs, the level of 2,3-BPG is very low in familial 2,3-BPG deficiency. Similar to high O
         <sub>
          2
         </sub>
         affinity Hb mutants, the p50 should be the first screening test that can be estimated from venous blood when the hemox-analyzer apparatus (described above) is not available.
        </p>
        <p class="headingAnchor" id="H3097968174">
         <span class="h2">
          Other disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other disorders can also cause congenital erythrocytosis.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Primary familial and congenital erythrocytosis/polycythemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary familial and congenital erythrocytosis/polycythemia (PFCP), also called benign erythrocytosis and autosomal dominant erythrocytosis, is an uncommon cause of erythrocytosis that is caused by mutations of
         <em>
          EPOR
         </em>
         (which encodes the EPO receptor).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical/laboratory characteristics
         </strong>
         – PFCP is characterized by:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevated RBC mass
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low serum EPO
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normal Hb-O
         <sub>
          2
         </sub>
         dissociation curve
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of progression to acute leukemia
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypersensitivity of erythroid progenitors to EPO
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Gene variants of
         <em>
          EPOR
         </em>
         associated with PFCP are typically inherited as an autosomal dominant trait, or it may be due to sporadic (de novo) mutations [
         <a href="#rid62">
          62-66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Analysis of 53 unrelated subjects with congenital erythrocytosis
         <em>
         </em>
         identified
         <em>
          EPOR
         </em>
         mutations in 9 percent [
         <a href="#rid64">
          64,67
         </a>
         ]. Most
         <em>
          EPOR
         </em>
         mutations encode a truncated receptor that lacks the C-terminal negative regulatory domain [
         <a href="#rid63">
          63,64,68,69
         </a>
         ]. The absence of a binding site for the negative regulator, hematopoietic phosphatase (HCP), triggers proliferation-inducing/apoptosis-inhibiting pathways that contribute to the erythrocytosis. An exception is the
         <em>
          EPOR
         </em>
         missense mutan
         <em>
          t, EPOR
         </em>
         p.Gln434Pro; its C-terminal tail was shown to increase EPO-R dimerization and stability, resulting in augmented JAK2 constitutive signaling and hypersensitivity to EPO [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="local">
          'Regulation of erythropoiesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H68553838">
         <span class="h3">
          <i>
           EPO
          </i>
          mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital erythrocytosis has rarely been associated with mutations of
         <em>
          EPO
         </em>
         .
        </p>
        <p>
         A five-generation family with autosomal dominant erythrocytosis had moderately increased EPO levels, no splenomegaly, and normal leukocyte and platelet numbers; normal Hb O
         <sub>
          2
         </sub>
         dissociation curve; and no mutations of
         <em>
          HIF2A, HIF1A, EPOR, PHD2, EGLN1
         </em>
         and
         <em>
          VHL
         </em>
         [
         <a href="#rid71">
          71
         </a>
         ]. A novel single nucleotide polymorphism was found at -136 nucleotides upstream of the
         <em>
          EPO
         </em>
         translation initiation site; this variant was identified in all seven affected family members and in none of eight unaffected relatives [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         In a multigenerational Norwegian family with erythrocytosis, the phenotype segregated with the
         <em>
          EPO
         </em>
         locus, according to a genome-wide association study (GWAS) [
         <a href="#rid73">
          73
         </a>
         ]. Exome sequencing revealed a single nucleotide deletion of exon 2. In an unrelated family, a different mutation was found in the same exon [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          POLYCYTHEMIA VERA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polycythemia vera (PV) is the most common cause of primary erythrocytosis. It is a myeloproliferative neoplasm (MPN) that is clinically manifest as erythrocytosis, variable increases of platelets and leukocytes, possible splenomegaly, and increased risk for thromboses. PV is a clonal disorder, and the vast majority of cases are caused by a specific acquired mutation,
         <em>
          JAK2
         </em>
         V617F. Clinical manifestations, diagnosis, management, and prognosis of PV are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4517.html" rel="external">
          "Clinical manifestations and diagnosis of polycythemia vera"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4534.html" rel="external">
          "Polycythemia vera and secondary polycythemia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2785067296">
         <span class="h2">
          Clonality of PV
         </span>
         <span class="headingEndMark">
          —
         </span>
         PV is a clonal disorder that arises from a single hematopoietic pluripotent stem cell; as a result, virtually all circulating myeloid cells are clonal in origin [
         <a href="#rid74">
          74,75
         </a>
         ]. The mutation is present in erythroid and myeloid cells, megakaryocytes, and a variable proportion of B lymphocytes; by contrast, most, but not all, T cells and natural killer cells remain polyclonal [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         A hallmark of the disease is the ability of PV bone marrow cells to form in vitro erythroid colonies in the absence of exogenous erythropoietin (EPO), a phenomenon that is not observed with progenitor cells from normal subjects [
         <a href="#rid77">
          77
         </a>
         ]. Prior to the identification of the causal mutation, this phenomenon was used as a diagnostic assay to distinguish PV from other causes of erythrocytosis [
         <a href="#rid69">
          69,78-80
         </a>
         ]. This property was also useful for characterizing primary familial and congenital polycythemia (PFCP) as a separate disease [
         <a href="#rid63">
          63,65,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H652649837">
         <span class="h2">
          <i>
           JAK2
          </i>
          mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutated
         <em>
          JAK2
         </em>
         is a hallmark of PV and is a major diagnostic criterion [
         <a href="#rid82">
          82
         </a>
         ]. However,
         <em>
          JAK2
         </em>
         V617F is not pathognomonic for PV; it is found in approximately half of patients with other MPNs (ie, essential thrombocythemia or primary myelofibrosis) and is seen rarely in other malignancies. The diagnosis of PV and clinical features of MPNs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">
          "Overview of the myeloproliferative neoplasms"
         </a>
         .)
        </p>
        <p>
         JAK/STAT signaling plays a pivotal role in erythroid proliferation and cell survival in response to EPO/EPO-R signaling [
         <a href="#rid83">
          83-86
         </a>
         ]. The
         <em>
          JAK2
         </em>
         V617F mutation dysregulates JAK2 tyrosine kinase activity by disrupting its inhibitory domain, thereby enabling constitutive phosphorylation of STATs, despite typically low EPO [
         <a href="#rid83">
          83-85,87
         </a>
         ]. This mutation was shown to recapitulate many properties of native PV erythroid progenitor cells, including EPO-independence and hypersensitivity of PV erythroid colonies.
        </p>
        <p>
         A small subset (eg, &lt;3 percent) of patients with PV are
         <em>
          JAK
         </em>
         V617F-negative. Most have a mutation within a 20-nucleotide region of exon 12 of
         <em>
          JAK2
         </em>
         [
         <a href="#rid88">
          88,89
         </a>
         ]. Very rarely, mutations are found in genes that facilitate
         <em>
         </em>
         JAK2 or STAT5 signal transduction (eg,
         <em>
          LNK,
         </em>
         <em>
          TET2
         </em>
         ,
         <em>
          CBL
         </em>
         ) [
         <a href="#rid90">
          90,91
         </a>
         ], while other patients have mutations of epigenetic regulators (eg, DNA and histone modifiers, such as
         <em>
          EZH2, TET2, ASXL1
         </em>
         ) [
         <a href="#rid91">
          91,92
         </a>
         ], or spliceosome machinery (eg,
         <em>
          SF3B1, SRSF2, U2AF1
         </em>
         ) that may contribute to development of PV
         <em>
         </em>
         [
         <a href="#rid91">
          91,93,94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H448978399">
         <span class="h2">
          Familial PV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 5 percent of patients with PV have relatives with PV or other MPNs that appear to be inherited as an autosomal dominant trait with incomplete penetrance [
         <a href="#rid95">
          95-98
         </a>
         ]. However, clinical PV or other MPNs in these families are acquired as a new mutation, occasionally at a younger age than seen in sporadic PV [
         <a href="#rid97">
          97
         </a>
         ]; some of these affected relatives acquire non-
         <em>
          JAK2
         </em>
         MPN-defining mutations such as
         <em>
          CALR
         </em>
         or
         <em>
          MPL
         </em>
         [
         <a href="#rid95">
          95-98
         </a>
         ]. This suggests familial PV may result from a combination of an inherited (germline) predisposition to mutation followed by a "second hit" somatic mutation that leads to acquired clonal hematopoiesis.
        </p>
        <p class="headingAnchor" id="H5555814">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Erythrocytosis
         </strong>
         – Erythrocytosis (also called polycythemia) refers to elevated hemoglobin (Hb) or hematocrit (Hct). Normal values for Hb and Hct vary with sex  (
         <a class="graphic graphic_table graphicRef127504" href="/z/d/graphic/127504.html" rel="external">
          table 3
         </a>
         ), age  (
         <a class="graphic graphic_table graphicRef57465" href="/z/d/graphic/57465.html" rel="external">
          table 2
         </a>
         ), and altitude of residence. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Absolute versus relative erythrocytosis
         </strong>
         – Erythrocytosis can be caused by increased red blood cell (RBC) mass (absolute erythrocytosis) and/or decreased plasma volume (relative erythrocytosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are numerous possible reasons for erythrocytosis  (
         <a class="graphic graphic_table graphicRef76036" href="/z/d/graphic/76036.html" rel="external">
          table 1
         </a>
         ); evaluation for the cause of erythrocytosis/polycythemia is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7075.html" rel="external">
          "Diagnostic approach to the patient with erythrocytosis/polycythemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary erythrocytosis
         </strong>
         – Polycythemia caused by an RBC-intrinsic process, due to an acquired mutation in hematopoietic cells or by an inherited (ie, germline) gene variant that renders proliferation of erythroid progenitors independent of/hypersensitive to erythropoietin (EPO).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secondary erythrocytosis
         </strong>
         – Erythrocytosis caused by circulating factors that stimulate erythropoiesis (eg, EPO, cobalt) as an appropriate physiologic response to hypoxia, or in congenital disorders of hypoxia sensing, and other mechanisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Congenital erythrocytosis
         </strong>
         – Inherited condition of increased RBC mass due to a mutation that affects the interaction of Hb with oxygen (O
         <sub>
          2
         </sub>
         )  (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ) or components of the hypoxia-sensing pathway  (
         <a class="graphic graphic_figure graphicRef53801" href="/z/d/graphic/53801.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regulation of erythropoiesis
         </strong>
         – EPO is the key regulator of proliferation and maturation of committed erythroid progenitors and maturing erythrocytes in bone marrow. In adults, EPO is primarily produced by the kidney in response to tissue hypoxia. Hypoxia inducible factor (HIF)-2 and HIF-1 regulate
         <em>
          EPO
         </em>
         transcription in a pathway that includes interactions with VHL and PHD2-dependent degradation. (See
         <a class="local">
          'Regulation of erythropoiesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital erythrocytosis
         </strong>
         – Inherited disorders of erythrocytosis include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Enhanced O
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          sensing
         </strong>
         – Mutations that cause increased EPO expression:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           VHL
          </em>
         </strong>
         – Chuvash erythrocytosis and other
         <em>
          VHL
         </em>
         gene mutations (see
         <a class="local">
          'Chuvash erythrocytosis'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           EGLN1
          </em>
         </strong>
         – Loss-of-function mutations of
         <em>
          EGLN1
         </em>
         (PHD2) (see
         <a class="local">
          'EGLN1 mutations'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           EPAS1
          </em>
         </strong>
         – Gain-of-function mutations of
         <em>
          EPAS1
         </em>
         (HIF-2 alpha) (see
         <a class="local">
          'EPAS1 mutations'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increased Hb-O
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          affinity
         </strong>
         (
         <a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">
          figure 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          High O
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          affinity Hb mutations
         </strong>
         – Various mutations (see
         <a class="local">
          'Hb mutants'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Congenital methemoglobinemia
         </strong>
         – Abnormal cytochrome b5 reductase and others (see
         <a class="local">
          'Congenital methemoglobinemia'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other disorders
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Primary familial and congenital erythrocytosis/polycythemia (PFCP)
         </strong>
         – Mutations of EPO-receptor (
         <em>
          EPOR
         </em>
         ) and other genes (see
         <a class="local">
          'Primary familial and congenital erythrocytosis/polycythemia'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          EPO mutations
         </strong>
         – Rare mutations (see
         <a class="local">
          'EPO mutations'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polycythemia vera (PV)
         </strong>
         – PV is a myeloproliferative neoplasm (MPN) manifested as erythrocytosis, variable leukocytosis and platelets, bone marrow hypercellularity, and propensity for thromboses. PV and other Philadelphia chromosome (Ph)-negative MPNs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">
          "Overview of the myeloproliferative neoplasms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clonality
         </strong>
         – PV is a clonal disorder of hematopoietic progenitors. (See
         <a class="local">
          'Clonality of PV'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           JAK2
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – Nearly all cases are caused by an acquired mutation (
         <em>
          JAK2
         </em>
         V617F) in a bone marrow progenitor cell. (See
         <a class="local">
          'JAK2 mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Familial PV
         </strong>
         – Rare cases of PV are seen in familial clusters; some are due to an inherited
         <em>
          JAK2
         </em>
         gene variant. (See
         <a class="local">
          'Familial PV'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3348198608">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Williams Manual of Hematology, 10th edition, Lichtman MA, Kaushansky K, Prchal JT, et al (Eds), McGraw Hill, 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gassmann M, Mairbäurl H, Livshits L, et al. The increase in hemoglobin concentration with altitude varies among human populations. Ann N Y Acad Sci 2019; 1450:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staub K, Haeusler M, Bender N, et al. Hemoglobin concentration of young men at residential altitudes between 200 and 2000 m mirrors Switzerland's topography. Blood 2020; 135:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 1990; 76:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andrea AD, Yoshimura A, Youssoufian H, et al. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11:1980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klingmüller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. Blood 2013; 122:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon D, Ponka P, Prchal JT. Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol 2011; 300:C1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1. Blood 1991; 78:2823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prchal JT, Gordeuk VR. HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension. Blood 2021; 137:2424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010; 2:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004; 103:3924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sergueeva AI, Miasnikova GY, Polyakova LA, et al. Complications in children and adolescents with Chuvash polycythemia. Blood 2015; 125:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood 2011; 118:5278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR, Key NS, Prchal JT. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica 2019; 104:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. Haematologica 2020; 105:e87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangaraju R, Song J, Kim SJ, et al. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv 2020; 4:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou AW, Knoche EM, Engle EK, et al. Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia. N Engl J Med 2016; 375:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poliakova LA. [Familial erythrocytosis among the residents of the Chuvash ASSR]. Probl Gematol Pereliv Krovi 1974; 19:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sergeyeva A, Gordeuk VR, Tokarev YN, et al. Congenital polycythemia in Chuvashia. Blood 1997; 89:2148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood 2006; 107:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003; 73:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy MJ, McMullin MF, Jowitt SN, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood 2003; 102:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica 2005; 90:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 2012; 97:9.
          </a>
         </li>
         <li class="breakAll">
          Prchal JT. Primary and Secondary Erythrocytoses. In: Williams Hematology, 9th edition, Kaushansky K, Lichtman MA, Prchal JT, et al (Eds), McGraw-Hill, New York 2016. p.871.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasic NL, Piterkova L, Huff C, et al. The phenotype of polycythemia due to Croatian homozygous VHL (571C&gt;G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C&gt;T:R200W). Haematologica 2013; 98:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanikova L, Lorenzo F, Yang C, et al. Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer. Blood 2013; 121:3918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenglet M, Robriquet F, Schwarz K, et al. Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood 2018; 132:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzo FR, Yang C, Lanikova L, et al. Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia. Br J Haematol 2013; 162:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrotta S, Roberti D, Bencivenga D, et al. Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria. N Engl J Med 2020; 382:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica 2012; 97:123.
          </a>
         </li>
         <li class="breakAll">
          FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease. ASH Clinical News. https://ashpublications.org/ashclinicalnews/news/5747/FDA-Committee-Votes-Against-Approval-of-Roxadustat (Accessed on May 17, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzo FR, Huff C, Myllymäki M, et al. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet 2014; 46:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 2008; 111:5400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gale DP, Harten SK, Reid CD, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 2008; 112:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrotta S, Stiehl DP, Punzo F, et al. Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica 2013; 98:1624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Sun MG, Matro J, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 2013; 121:2563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacak K, Jochmanova I, Prodanov T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013; 31:1690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 2013; 91:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal N, Mojica-Henshaw MP, Simmons ED, et al. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci 2007; 4:232.
          </a>
         </li>
         <li class="breakAll">
          Agarwal AM, Prchal JT. Methemoglobinemia and Other Dyshemoglobinemias. In: Williams Hematology, 9th edition, Kaushansky K, Lichtman MA, Prchal JT, et al (Eds), McGraw-Hill, New York 2016. p.879.
         </li>
         <li class="breakAll">
          Agarwal N, Nagel RL, Prchal JT. Dyshemoglobinemias. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed, Steinberg M (Ed), Cambridge UP, Cambridge 2009. p.607.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosa R, Prehu MO, Beuzard Y, Rosa J. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest 1978; 62:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galacteros F, Rosa R, Prehu MO, et al. [Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis]. Nouv Rev Fr Hematol 1984; 26:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 1992; 80:2643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emanuel PD, Eaves CJ, Broudy VC, et al. Familial and congenital polycythemia in three unrelated families. Blood 1992; 79:3019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang LJ, Shen YM, Bulut GB. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol 2010; 148:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001; 68:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003; 17:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquier F, Marty C, Balligand T, et al. New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica 2018; 103:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maran J, Jedlickova K, Stockton D, et al. Finding the novel molecular defect in a family with high erythropoietin autosomal dominant polycythemia. Blood 2003; 102:162b.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzo FR, Margraf R, Swierczek S, et al. A Novel EPO Gene Mutation In a Family With Autosomal Dominant Polycythemia. Blood (ASH Annual Meeting Abstracts) 2013; 122:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zmajkovic J, Lundberg P, Nienhold R, et al. A Gain-of-Function Mutation in EPO in Familial Erythrocytosis. N Engl J Med 2018; 378:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swierczek S, Lima LT, Tashi T, et al. Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 2015; 29:2432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005; 12:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974; 290:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 1996; 22 Suppl 1:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih LY, Lee CT, See LC, et al. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. Eur J Clin Invest 1998; 28:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prchal JT, Crist WM, Goldwasser E, et al. Autosomal dominant polycythemia. Blood 1985; 66:1208.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 2014; 28:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011; 96:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119:4480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RL, Purvis JD 3rd, Weick JK. Familial polycythemia vera. Cleve Clin J Med 1989; 56:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brubaker LH, Wasserman LR, Goldberg JD, et al. Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. Am J Hematol 1984; 16:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tashi T, Swierczek S, Prchal JT. Familial MPN Predisposition. Curr Hematol Malig Rep 2017; 12:442.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7106 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Williams Manual of Hematology, 10th edition, Lichtman MA, Kaushansky K, Prchal JT, et al (Eds), McGraw Hill, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31257609" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The increase in hemoglobin concentration with altitude varies among human populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16189263" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32043119" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hemoglobin concentration of young men at residential altitudes between 200 and 2000 m mirrors Switzerland's topography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/719172" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163696" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Human erythropoietin receptor: cloning, expression, and biologic characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1848667" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8343951" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7889566" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11292861" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11292862" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21830968" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Oxygen sensing, homeostasis, and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23733342" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Erythrocytosis: the HIF pathway in control.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494350" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7539918" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7836384" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Purification and characterization of hypoxia-inducible factor 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21368293" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hypoxia. 5. Hypoxia and hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651478" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1954373" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33956067" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20836033" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oxygen homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726398" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573974" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Complications in children and adolescents with Chuvash polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12415268" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876117" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30872370" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31289208" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32203583" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27518686" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4431763" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : [Familial erythrocytosis among the residents of the Chuvash ASSR].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9058738" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Congenital polycythemia in Chuvashia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393546" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mutations in the VHL gene in sporadic apparently congenital polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16210343" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12844285" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702509" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642677" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Congenital polycythemias/erythrocytoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21933857" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21933857" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23403324" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The phenotype of polycythemia due to Croatian homozygous VHL (571C&gt;G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C&gt;T:R200W).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23538339" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29891534" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23772956" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32101665" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effects of Germline VHL Deficiency on Growth, Metabolism, and Mitochondria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16407130" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828119" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828119" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25129147" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A genetic mechanism for Tibetan high-altitude adaptation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18184961" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378852" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18650473" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23716564" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22931260" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23361906" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23509317" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : New syndrome of paraganglioma and somatostatinoma associated with polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090011" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17952198" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17952198" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17952198" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/152321" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6326048" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : [Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1421379" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1316790" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Familial and congenital polycythemia in three unrelated families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9025165" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Erythropoietin receptor mutations and human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9292543" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1954391" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096014" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Advances in understanding the pathogenesis of primary familial and congenital polycythaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11559951" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Genetic heterogeneity of primary familial and congenital polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192789" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14560779" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29269524" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Finding the novel molecular defect in a family with high erythropoietin autosomal dominant polycythemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A Novel EPO Gene Mutation In a Family With Autosomal Dominant Polycythemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29514032" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A Gain-of-Function Mutation in EPO in Familial Erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/967201" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Polycythemia vera: stem-cell and probable clonal origin of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369983" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725900" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Polycythemia vera and other primary polycythemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4827655" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Letter: Bone-marrow responses in polycythemia vera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9025164" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8951779" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9726038" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4052634" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Autosomal dominant polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4052634" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Autosomal dominant polycythemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781101" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837627" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15858187" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A gain-of-function mutation of JAK2 in myeloproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863514" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Identification of an acquired JAK2 mutation in polycythemia vera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15793561" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267906" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984312" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21653328" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : New mutations and pathogenesis of myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24413320" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21972209" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Epigenetics and mutations in chronic myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22323480" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431577" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2691118" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Familial polycythemia vera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6720682" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12829587" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29027642" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Familial MPN Predisposition.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
